Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers
- PMID: 17211705
- DOI: 10.1007/s10620-006-9490-9
Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers
Abstract
Low-dose omeprazole is superior to full-dose famotidine in maintenance therapy for gastroesophageal reflux disease, whereas "on-demand" famotidine is more effective for relief of episodes of heartburn. To explain this apparent discrepancy, intragastric pH was measured for 24-hr seven times in eight Japanese Helicobacter pylori-negative cytochrome P450 2C19 extensive metabolizers; on Days 1, 8, and 15 of repeated administration of 10 mg of omeprazole once daily and of 20 mg of famotidine twice daily and before medication. During repeated administration of omeprazole, mean intragastric pH and % time that intragastric pH > 4.0 were significantly higher and became greater. With famotidine, although these parameters were significantly higher, the degrees became smaller. Consequently, acid-suppressive effect was in the order; omeprazole < famotidine on Day 1, omeprazole approximately famotidine on Day 8, and omeprazole >famotidine on Day 15. This discrepancy possibly results from the "potentiation" of acid-suppressive effect of omeprazole and the "tolerance" phenomenon in respect to famotidine.
Similar articles
-
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.Clin Pharmacol Ther. 2006 Nov;80(5):539-48. doi: 10.1016/j.clpt.2006.08.010. Clin Pharmacol Ther. 2006. PMID: 17112810 Clinical Trial.
-
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.Clin Pharmacol Ther. 2006 Jan;79(1):144-52. doi: 10.1016/j.clpt.2005.09.012. Clin Pharmacol Ther. 2006. PMID: 16413249 Clinical Trial.
-
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.Aliment Pharmacol Ther. 2005 Jul 1;22(1):67-74. doi: 10.1111/j.1365-2036.2005.02523.x. Aliment Pharmacol Ther. 2005. PMID: 15963082 Clinical Trial.
-
CYP2C19 polymorphism and proton pump inhibitors.Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):2-8. doi: 10.1111/j.1600-0773.2004.pto950102.x. Basic Clin Pharmacol Toxicol. 2004. PMID: 15245569 Review.
-
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.Clin Pharmacol Ther. 2000 Jun;67(6):684-9. doi: 10.1067/mcp.2000.106826. Clin Pharmacol Ther. 2000. PMID: 10872651 Review.
Cited by
-
Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.World J Gastrointest Pharmacol Ther. 2014 May 6;5(2):57-62. doi: 10.4292/wjgpt.v5.i2.57. World J Gastrointest Pharmacol Ther. 2014. PMID: 24868486 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources